Exactly....I think you'll find these distinctions are made because they address different 'markets' that attract different funding and revenue streams.
Don't over-analyse the table....management are doing their best to explain what they can whilst keeping 'in confidence' negotiations under their hat as per regulatory requirements..
The lack of detail on 'therapeutics' is a perfect example.
But....anyone who has followed TLX would understand the upside in that space.
Screening v monitoring, page-3
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.0¢ |
Change
-0.010(1.75%) |
Mkt cap ! $59.09M | |||
| Open | High | Low | Value | Volume |
| 57.0¢ | 57.0¢ | 54.0¢ | $96.73K | 176.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12 | 55.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.0¢ | 7999 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |